Novartis Venture Fund has helped seed a T-cell drug developer founded from Seattle Children's Hospital, Benaroya Research Institute and MIGAL Galilee.

Lepu Medical's immuno-oncology spinoff secured $186m in a round co-led by Ping An Capital and the Sunshine Insurance-backed Riverhead Capital.

The T-cell drug developer has launched with $20m from a seed round co-led by corporate venturing unit Novartis Venture Fund.

NetScientific is poised to acquire EMV Capital in an all-share deal after appointing the latter's managing director as its chief executive in May.

Sinpoharm-backed joint venture Sinopharm-CICC was among the investors in a $43.2m round that boosted the antimicrobial drug developer's total funding to near $150m.

The mental well-being and recruitment services provider has launched an investment vehicle that will provide up to $950,000 per deal.

The UK regional tech transfer alliance's Seed Investment Fund expects to close its first investments in coming months, targeting sectors including healthcare and data.

Osage University Partners-backed PMV has pushed its funding total to $236m as it further commercialises Princeton research stretching back to 1979.

Pfizer, Sanofi, Vertex Pharmaceuticals, Merck & Co and Amgen are in line for exits after the immunotherapy developer filed to go public.

Existing investor Hikma Ventures returned for a series B round that came amidst increased demand for Lemonaid's remote healthcare services.